FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891812963> ?p ?o ?g. }

• W2891812963 endingPage "9030" @default.
• W2891812963 startingPage "9030" @default.
• W2891812963 abstract "9030 Background: Pembrolizumab (pembro) has shown antitumor activity in patients (pts) with advanced NSCLC and is standard-of-care therapy for pts with PD-L1‒expressing tumors (first-line, TPS ≥50%; previously treated, TPS ≥1%). KEYNOTE-001, an open-label phase 1b study, evaluated pembro monotherapy in treatment-naive or previously treated pts with advanced NSCLC (NCT01295827). We report a 4-y update of KEYNOTE-001. Methods: Pts had confirmed locally advanced/metastatic NSCLC and provided a contemporaneous tumor tissue sample for evaluation of PD-L1 levels by IHC using the 22C3 antibody. Pts received pembro 2 mg/kg Q3W or 10 mg/kg Q2W or Q3W. Primary efficacy endpoint was ORR. OS was a secondary endpoint. Results: As of data cutoff (Sep 1, 2017), among 550 pts enrolled (treatment-naive, n = 101; previously treated, n = 449), median (range) follow-up was 46.5 (37.7–63.8) mo. ORR (by investigator per irRC) was 41.6 % (95% CI, 31.9–51.8) for treatment-naive pts and 22.9% (95% CI, 19.1–27.1) for previously treated pts. Median OS was 22.3 mo (95% CI, 17.1–32.3) for treatment-naive pts and 10.5 mo (95% CI, 8.6–13.2) for previously treated pts; estimated 4-y OS rates were 27.2% and 16.4 %, respectively. Kaplan-Meier curves for OS appeared to plateau after 42 mo for treatment-naive pts and 36 mo for previously treated pts. Increased PD-L1 expression was associated with improved OS (Table). Immune-mediated AEs occurred in 24.8% of treatment-naive and 17.4% of previously treated pts. No additional grade 5 treatment-related AEs occurred (compared with 3-y follow-up; data cutoff Sep 1, 2016). Conclusions: Pembro provides long-term OS benefit for both treatment-naive and previously treated advanced NSCLC that expresses PD-L1. These data represent the longest efficacy and safety follow-up for pts with advanced NSCLC treated with pembro. Clinical trial information: NCT01295827.OS in subgroups defined by PD-L1 TPS. Treatment-Naive (N = 101) Previously Treated (N = 449) n Median (95% CI), mo Est. 4-y rate n Median (95% CI), mo Est. 4-y rate TPS ≥50% 27 35.4 (20.3‒NE) 48.1% 138 15.4 (10.6‒18.8) 24.8% TPS 1%–49% 52 19.5 (10.7‒26.3) NE 168 8.5 (6.0‒12.6) 15.6% TPS ≤1% Not reported* 90 8.6 (5.5‒10.6) 6.5% NE = not estimable. *Due to small pt numbers (n = 12)." @default.
• W2891812963 created "2018-09-27" @default.
• W2891812963 creator A5004864286 @default.
• W2891812963 creator A5012748795 @default.
• W2891812963 creator A5021579570 @default.
• W2891812963 creator A5029805571 @default.
• W2891812963 creator A5034739279 @default.
• W2891812963 creator A5045982804 @default.
• W2891812963 creator A5052730435 @default.
• W2891812963 creator A5055548058 @default.
• W2891812963 creator A5056098854 @default.
• W2891812963 creator A5060287300 @default.
• W2891812963 creator A5062894702 @default.
• W2891812963 creator A5069270989 @default.
• W2891812963 creator A5070570779 @default.
• W2891812963 creator A5088178599 @default.
• W2891812963 creator A5090324173 @default.
• W2891812963 creator A5091281351 @default.
• W2891812963 date "2018-05-20" @default.
• W2891812963 modified "2023-10-16" @default.
• W2891812963 title "4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001." @default.
• W2891812963 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.9030" @default.
• W2891812963 hasPublicationYear "2018" @default.
• W2891812963 type Work @default.
• W2891812963 sameAs 2891812963 @default.
• W2891812963 citedByCount "12" @default.
• W2891812963 countsByYear W28918129632019 @default.
• W2891812963 countsByYear W28918129632020 @default.
• W2891812963 countsByYear W28918129632021 @default.
• W2891812963 crossrefType "journal-article" @default.
• W2891812963 hasAuthorship W2891812963A5004864286 @default.
• W2891812963 hasAuthorship W2891812963A5012748795 @default.
• W2891812963 hasAuthorship W2891812963A5021579570 @default.
• W2891812963 hasAuthorship W2891812963A5029805571 @default.
• W2891812963 hasAuthorship W2891812963A5034739279 @default.
• W2891812963 hasAuthorship W2891812963A5045982804 @default.
• W2891812963 hasAuthorship W2891812963A5052730435 @default.
• W2891812963 hasAuthorship W2891812963A5055548058 @default.
• W2891812963 hasAuthorship W2891812963A5056098854 @default.
• W2891812963 hasAuthorship W2891812963A5060287300 @default.
• W2891812963 hasAuthorship W2891812963A5062894702 @default.
• W2891812963 hasAuthorship W2891812963A5069270989 @default.
• W2891812963 hasAuthorship W2891812963A5070570779 @default.
• W2891812963 hasAuthorship W2891812963A5088178599 @default.
• W2891812963 hasAuthorship W2891812963A5090324173 @default.
• W2891812963 hasAuthorship W2891812963A5091281351 @default.
• W2891812963 hasConcept C121608353 @default.
• W2891812963 hasConcept C126322002 @default.
• W2891812963 hasConcept C143998085 @default.
• W2891812963 hasConcept C203092338 @default.
• W2891812963 hasConcept C2777701055 @default.
• W2891812963 hasConcept C2780057760 @default.
• W2891812963 hasConcept C535046627 @default.
• W2891812963 hasConcept C71924100 @default.
• W2891812963 hasConcept C90924648 @default.
• W2891812963 hasConceptScore W2891812963C121608353 @default.
• W2891812963 hasConceptScore W2891812963C126322002 @default.
• W2891812963 hasConceptScore W2891812963C143998085 @default.
• W2891812963 hasConceptScore W2891812963C203092338 @default.
• W2891812963 hasConceptScore W2891812963C2777701055 @default.
• W2891812963 hasConceptScore W2891812963C2780057760 @default.
• W2891812963 hasConceptScore W2891812963C535046627 @default.
• W2891812963 hasConceptScore W2891812963C71924100 @default.
• W2891812963 hasConceptScore W2891812963C90924648 @default.
• W2891812963 hasIssue "15_suppl" @default.
• W2891812963 hasLocation W28918129631 @default.
• W2891812963 hasOpenAccess W2891812963 @default.
• W2891812963 hasPrimaryLocation W28918129631 @default.
• W2891812963 hasRelatedWork W3088074323 @default.
• W2891812963 hasRelatedWork W3094659495 @default.
• W2891812963 hasRelatedWork W3166462580 @default.
• W2891812963 hasRelatedWork W3177224496 @default.
• W2891812963 hasRelatedWork W3206683137 @default.
• W2891812963 hasRelatedWork W4221031788 @default.
• W2891812963 hasRelatedWork W4229043315 @default.
• W2891812963 hasRelatedWork W4304690509 @default.
• W2891812963 hasRelatedWork W4313478647 @default.
• W2891812963 hasRelatedWork W4322775203 @default.
• W2891812963 hasVolume "36" @default.
• W2891812963 isParatext "false" @default.
• W2891812963 isRetracted "false" @default.
• W2891812963 magId "2891812963" @default.
• W2891812963 workType "article" @default.